Trial reportThe American journal of psychiatry2017
A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.
Trial report in The American journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 65 citations in OpenAlex.
- Efficacy of internet-delivered acceptance and commitment therapy for severe health anxiety: results from a randomized, controlled trial.Psychological medicine · 2021Trial
- Effect of Internet vs Face-to-Face Cognitive Behavior Therapy for Health Anxiety: A Randomized Noninferiority Clinical Trial.JAMA psychiatry · 2020Trial
- The effect of health literacy on health anxiety among young women.Postepy psychiatrii neurologii · 2026Article
- Parkinson's Disease as Illness Anxiety Disorder: A Rare Case Report.Clinical case reports · 2025Article
- Illness Anxiety Disorder: A Review of the Current Research and Future Directions.Current psychiatry reports · 2024Review
- Role of Selective Serotonin Reuptake Inhibitors in the Treatment of Hypochondriasis: A Systematic Review.Cureus · 2023Review
- New challenges in facing cyberchondria during the coronavirus disease pandemic.Current opinion in behavioral sciences · 2022Review
- Health Anxiety and Its Relationship to Thyroid-Hormone-Suppression Therapy in Patients with Differentiated Thyroid Cancer.Cancers · 2022Article
- Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial.PharmacoEconomics - open · 2022Article
- The Relationship Between 5-Hydroxytryptamine and Its Metabolite Changes With Post-stroke Depression.Frontiers in psychiatry · 2022Review
- Curing somatisation-induced paraplegia with experimental dice-based affective modulation.BMJ case reports · 2021Article
- Article
- Differential Treatment Response Between Hypochondriasis With and Without Prominent Somatic Symptoms.Frontiers in psychiatry · 2021Article
- Managing Problematic Usage of the Internet and Related Disorders in an Era of Diagnostic Transition: An Updated Review.Clinical practice and epidemiology in mental health : CP & EMH · 2021Review
- Why health anxiety needs to be recognised in hospital practice.Clinical medicine (London, England) · 2020Review
- When Imagination Becomes a Disease: Dealing With Hypochondriacal Patients in Clinical Practice.Ochsner journal · 2019Article
- Recent Advances in the Understanding and Treatment of Health Anxiety.Current psychiatry reports · 2018Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectivePrior studies of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CBT). This study examined whether joint treatment offers additional benefit.
methodPatients with DSM-IV hypochondriasis (N=195) were randomly assigned to one of four treatments-placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and CBT. Evaluations assessed hypochondriasis, other psychopathology, adverse events, functional status, and quality of life. The primary analysis assessed outcome at week 24 among the intent-to-treat sample, with responders defined as having a 25% or greater improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M). The Cochran-Armitage trend test assessed the hypothesized pattern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment.
resultsThe predicted pattern of response was statistically significant, as shown by the following responder rates: joint treatment group, 47.2%; single active treatment group, 41.8%; and placebo group, 29.6%. Responder rates for each active treatment were not significantly different from the rate for placebo. Secondary analyses of the Whiteley Index as a continuous measure revealed that, compared with placebo, fluoxetine (but not CBT) was significantly more effective at week 24 in reducing hypochondriasis and had a significantly faster rate of improvement over 24 weeks. Fluoxetine also resulted in significantly less anxiety and better quality of life than placebo. Dropout rates did not differ between groups, and treatment-emergent adverse events were evenly distributed.
conclusionsThis study supports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis. Joint treatment provided a small incremental benefit. Because approximately 50% of patients did not respond to the study treatments, new or more intensive approaches are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.